# Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

> **NCT00311467** · PHASE3 · TERMINATED · sponsor: **Central European Cooperative Oncology Group** · enrollment: 172 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Capecitabine, Interferon, Interleukin

## Key facts

- **NCT ID:** NCT00311467
- **Lead sponsor:** Central European Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 172 (ACTUAL)
- **Why stopped:** no patient recruitment
- **Last updated:** 2012-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311467, "Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00311467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*